Vimarsana
Biggest News Aggregation in the World

Q Submission Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Q Submission Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Q Submission Program Today - Breaking & Trending Today

Medical Device Legal News - Vimarsana News

Medical Device Legal News

This weekly news program, hosted by partner Sam Bernstein, covers recent legal and compliance developments for medical device companies, including…

FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Healthcare - Vimarsana News

FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Healthcare

After an over decade-long discourse amongst interested stakeholders, on October 3, 2023, FDA unveiled its proposed rule and policy to increase oversight over LDTs.

Source: mondaq.com
FDA's Proposed Rule for Oversight of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy - Key Considerations & Open Questions | Goodwin - Vimarsana News

FDA's Proposed Rule for Oversight of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy - Key Considerations & Open Questions | Goodwin

After an over decade-long discourse amongst interested stakeholders, on October 3, 2023, FDA unveiled its proposed rule and policy to increase oversight over LDTs. If...

FDA Roundup: June 2, 2023 - Vimarsana News

FDA Roundup: June 2, 2023

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA provided an...

Dems' Medicare win faces long, uncertain future- POLITICO - Vimarsana News

Dems' Medicare win faces long, uncertain future- POLITICO

Senate Democrats pushed through a provision of the Inflation Reduction Act that would allow Medicare to negotiate prescription drug prices with drugmakers.